(Q74599519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

A Coates

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

O Pagani

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

A Goldhirsch

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 February 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

15-26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Treatment of primary breast cancer with chemotherapy and tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Aust

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Formulating questions and locating primary studies for inclusion in systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Present and future projects of the International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990068-8

7 January 2021

10.1016/S0305-7372(98)90068-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606365%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference